Sociedad Americana de Hirudoterapia

Applications of leech therapy in medicine: a systematic review

Hosseini M, Jadidi A, Derakhshan Barjoei MM, Salehi M (2024) · Frontiers in Medicine · n=12

RCT evidence detailTrial reference
GRADE LowCohort / case seriesCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Hosseini M 202412
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
PRISMA-compliant systematic review of clinical trials of leech therapy across all indications (PubMed/Scopus/Web of Science through April 2023); Arak University of Medical Sciences and Shahid Beheshti University, Iran
Sample size (n)
12
Intervention
Whole-leech (Hirudo medicinalis and regional species) therapy across heterogeneous indications including knee OA, varicose veins, infertility, diabetes/lipid metabolism, hypertension
Comparator
Standard care, sham, or pharmacological comparators across the 12 included trials (heterogeneous)
Primary endpoint
Qualitative synthesis of efficacy and adverse-event patterns of leech therapy across clinical conditions
Primary result
12 trials met inclusion criteria; review concludes leech therapy has 'successful outcomes' across hormonal/metabolic complications, cardiovascular conditions, and inflammatory diseases; complications acknowledged but described as manageable with preventive measures; authors call for higher-quality RCTs
Follow-up duration
Variable across included trials

Key Findings

  • 12 clinical trials of leech therapy across all indications (through April 2023)
  • Authors note efficacy signals in metabolic, cardiovascular, and inflammatory conditions
  • Cochrane bias analysis identified considerable heterogeneity in methods and risk of bias
  • Complications acknowledged: localized pain, mild bleeding, occasional infection
  • Authors call for larger high-quality RCTs across indications

Limitations

  • Wide indication scope prevents condition-specific GRADE pooling
  • Mixed inclusion of low-quality trials weakens overall confidence
  • Limited to English-language databases; missed substantial Russian, Turkish, Persian, Hindi/Sanskrit-language hirudotherapy literature
  • Cochrane bias tool used without explicit risk-of-bias table per indication
  • 12 trials is a small base for multi-indication conclusions

Clinical Implications

Hosseini 2024 is a useful contemporary snapshot of the leech-therapy clinical literature but should not be used in isolation to support specific indication claims. For ASH clinicians and researchers, the review reinforces (1) the persistent quality gap between hirudotherapy and pharmacologic comparator literatures, (2) the need for trial-quality standardization (CONSORT-compliant reporting), and (3) the value of indication-specific systematic reviews (e.g., Lauche 2014 for knee OA, Rajaram 2024 for breast surgery) over broad multi-indication reviews.

Related Trials

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.